Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Mean Platelet Volume as a Prognostic Marker in Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Combined Chemotherapy

  • Tunce, Tolga (Department of Medical Oncology, Gata Haydarpasa Training Hospital) ;
  • Ozgun, Alpaslan (Department of Medical Oncology, Gata Haydarpasa Training Hospital) ;
  • Emirzeoglu, Levent (Department of Medical Oncology, Gata Haydarpasa Training Hospital) ;
  • Celik, Serkan (Department of Medical Oncology, Gata Haydarpasa Training Hospital) ;
  • Bilgi, Oguz (Department of Medical Oncology, Gata Haydarpasa Training Hospital) ;
  • Karagoz, Bulent (Department of Medical Oncology, Gata Haydarpasa Training Hospital)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Recent studies have revealed a prognostic impact of the MPV (mean platelet volume)/platelet count ratio in terms of survival in advanced non-small cell lung cancer. However, there has been no direct analysis of the survival impact of MPV in patients with mCRC. The aim of the study is to evaluate the pretreatment MPV of patients with metastatic and non-metastatic colorectal cancer (non-mCRC) and also the prognostic significance of pretreatment MPV to progression in mCRC patients treated with bevacizumab-combined chemotherapy. Materials and Methods: Fifty-three metastatic and ninety-five non-metastatic colorectal cancer patients were included into the study. Data on sex, age, lymph node status, MPV, platelet and platecrit (PCT) levels were obtained retrospectively from the patient medical records. Results: The MPV was significantly higher in the patients with mCRC compared to those with non-mCRC ($7.895{\pm}1.060$ versus $7.322{\pm}1.136$, p=0.013). The benefit of bevacizumab on PFS was significantly greater among the patients with low MPV than those with high MPV. The hazard ratio (HR) of disease progression was 0.41 (95%CI, 0.174-0.986; p=0.04). In conclusion, despite the retrospective design and small sample size, MPV can be considered a prognostic factor for mCRC patients treated with bevacizumab-combined chemotherapy.

Keywords

References

  1. Amado RG, Wolf M, Peeters M, et al (2008). Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 26, 1626-34. https://doi.org/10.1200/JCO.2007.14.7116
  2. Aykan NF, Yildiz I, Sen F, et al (2013). Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer patients treated with bevacizumab-based therapy. Med Oncol, 30, 679. https://doi.org/10.1007/s12032-013-0679-4
  3. Bar J, Spencer S, Morgan S, et al (2014). Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: retrospective analysis of the Horizon I study. Clin Colorectal Cancer, 13, 46-53. https://doi.org/10.1016/j.clcc.2013.11.002
  4. Cai J, Ma H, Huang F, et al (2013). Correlation of bevacizumabinduce hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systemeatic review and meta-analysis. World J Surg Oncol, 11, 306. https://doi.org/10.1186/1477-7819-11-306
  5. Cho SY, Yang JJ, You E, et al (2013). Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets, 24, 375-7. https://doi.org/10.3109/09537104.2012.701028
  6. Dirican A, Varol U, Kucukzeybek Y, et al (2014). Treatment of metastatic colorectalcancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab? Asian Pac J Cancer Prev, 15, 4781-6. https://doi.org/10.7314/APJCP.2014.15.12.4781
  7. Giantonnio B, Catalano B, Meropol N, et al (2007). Bevacizumab in combination with oxaliplatin fluorouracil, and leucoverin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study e3200. J Clin Oncol, 25, 1539-44. https://doi.org/10.1200/JCO.2006.09.6305
  8. Hurwitz H, Fehrenbacher L, Novotny W, et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucoverin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42. https://doi.org/10.1056/NEJMoa032691
  9. Inagaki N, Kibata K, Tamaki T, Shimuzu T, Nomura S (2014). Prognostic impact of the mean platelet volume/platelet count ration in terms of survival in advanced non-small cell lung cancer. Lung Cancer, 83, 97-101. https://doi.org/10.1016/j.lungcan.2013.08.020
  10. Jemal A, Center MM, DeSantis C, Ward EM (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-7. https://doi.org/10.1158/1055-9965.EPI-10-0437
  11. Kabbinavar F, Schulz J, McCleod M, et al (2005). Addition of bevacizumab to bolous fluorouracil and leucoverin in firstline metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol, 23, 3697-705. https://doi.org/10.1200/JCO.2005.05.112
  12. Kemal Y, Yucel I, Ekiz K, et al (2014). Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pac J Cancer Prev, 15, 2651-4. https://doi.org/10.7314/APJCP.2014.15.6.2651
  13. Kilincalp S, Ekiz F, Basar O, et al (2013). Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelet, early online, 1-3.
  14. Matowicka-Karna J, Kamocki Z, Polinska B, Osada J, Kemona H (2013). Platelets and inflammatory markers in patients with gastric cancer. Clin Dev Immunol, 2013, 401623.
  15. Mutlu H, Artis TA, Erden A, Akca A (2013). Alteration in mean platelet volume and placticrit values in patients with cancer that developed thrombosis. Clin Appl Thrombosis/Hemostasis, 19, 331-3. https://doi.org/10.1177/1076029611433644
  16. Oge T, Yalcin O.T, Ozalp S.S, Isikci T (2013). Platelet volume as a parameter for platelet activation in patients with endometrial cancer. J Obstets Gynecol, 33, 301-4. https://doi.org/10.3109/01443615.2012.758089
  17. Ozdemir Y, Akin ML, Sucullu I, Balta AZ, Yucel E (2014). Pretreatment neutrophil/lymphocyte ratio as a prognostic aid in colorectal cancer. Asian Pac J Cancer Prev, 15, 2647-50. https://doi.org/10.7314/APJCP.2014.15.6.2647
  18. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42. https://doi.org/10.7314/APJCP.2013.14.9.5237
  19. Van Custen E, Rivera F, Berry S, et al (2009). Safety and efficacy of fist-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluropyrmidines in metastatic colorectal cancer: the BEAT study. Ann Oncol, 20, 1842-7. https://doi.org/10.1093/annonc/mdp233

Cited by

  1. Evaluation of Platelet Indices in Lung Cancer Patients vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7599
  2. Mean Platelet Volume Could be a Possible Biomarker for Papillary Thyroid Carcinomas vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2671
  3. Analyses of Multiple Factors for Determination of "Selected Patients" Who Should Receive Rechallenge Treatment in Metastatic Colorectal Cancer: a Retrospective Study from Turkey vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2833
  4. Platelets and immunity: the interplay of mean platelet volume in health and disease vol.8, pp.5, 2015, https://doi.org/10.1586/17474086.2015.1069703
  5. Mean Platelet Volume as a Biomarker for Thyroid Carcinoma vol.101, pp.1-2, 2016, https://doi.org/10.9738/INTSURG-D-15-00123.1
  6. Mean Platelet Volume as an Independent Predictive Marker for Pathologic Complete Response after Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2089
  7. Diagnostic and prognostic roles of the mean platelet volume in malignant tumors: a systematic review and meta-analysis vol.27, pp.8, 2016, https://doi.org/10.3109/09537104.2016.1169265
  8. Evaluation of the relationship between c-Kit expression and mean platelet volume in classic Kaposi's sarcoma vol.91, pp.4, 2016, https://doi.org/10.1590/abd1806-4841.20164331
  9. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer pp.17437555, 2017, https://doi.org/10.1111/ajco.12834
  10. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer pp.17526981, 2017, https://doi.org/10.1111/crj.12605
  11. Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis vol.107, pp.2, 2018, https://doi.org/10.1007/s12185-017-2348-4
  12. Evaluation of platelet indices as diagnostic biomarkers for colorectal cancer vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-29293-x
  13. Mean platelet volume predicts survival in pancreatic cancer patients with synchronous liver metastases vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-24539-0
  14. Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study pp.1699-3055, 2019, https://doi.org/10.1007/s12094-019-02037-7